Plasmodium immunotherapy for advanced platinum-resistant ovarian cancer
Part of Infections clinical trials.
This trial tests Plasmodium immunotherapy in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the treatment can slow tumor growth or improve cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 80, inclusive.
- Your ovarian cancer was confirmed by pathology testing, and it is stage III or IV.
- Your cancer is “platinum-resistant” and scans show it has progressed after platinum chemotherapy.
- You have at least one measurable tumor area on scans, or your tumor marker stays elevated.
- Your overall health score (ECOG) is 0 or 1, and you’re expected to live at least 3 months.
- Your blood counts and albumin are high enough, and you can use reliable birth control if pregnancy is possible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.
This Phase 1/2 study tests an immune treatment made from Plasmodium (a malaria-related organism) in people with advanced solid cancers. It aims to see how well the treatment can control tumors and is primarily focused on early safety and whether it shows signs of benefit.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.